Advances in TCDD-inducible poly(ADP-ribose) polymerase (TiPARP/PARP7) research: From molecular mechanisms to therapeutic applications
- 7 December 2025
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 244, 117618
Abstract
No abstract availableKeywords
Funding Information
- Medical Science and Technology Project of Zhejiang Province (2023KY210)
This publication has 120 references indexed in Scilit:
- Unleashing viral mimicry: A combinatorial strategy to enhance the efficacy of PARP7 inhibitorsBioEssays, 2024
- PARP7i Clinical Candidate RBN‐2397 Exerts Antiviral Activity by Modulating Interferon‐β Associated Innate Immune Response in MacrophagesDrug Development Research, 2024
- ADP-ribosylation, a multifaceted modification: Functions and mechanisms in aging and aging-related diseasesAgeing Research Reviews, 2024
- Quantification of PARP7 Protein Levels and PARP7 Inhibitor Target Engagement in Cells Using a Split Nanoluciferase System2022
- Aryl hydrocarbon receptor (AHR) functions in infectious and sterile inflammation and NAD+-dependent metabolic adaptationArchives of Toxicology, 2021
- Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylationBiochemical Pharmacology, 2019
- From TCDD-mediated toxicity to searches of physiologic AHR functionsBiochemical Pharmacology, 2018
- The aryl hydrocarbon receptor regulates the expression of TIPARP and its cis long non-coding RNA, TIPARP-AS1Biochemical and Biophysical Research Communications, 2018
- Identification of Protein Substrates of Specific PARP Enzymes Using Analog-Sensitive PARP Mutants and a “Clickable” NAD+ Analog2017
- TCDD-Inducible Poly(ADP-ribose) Polymerase: A Novel Response to 2,3,7,8-Tetrachlorodibenzo-p-dioxinBiochemical and Biophysical Research Communications, 2001